TRANSPLANTATION OF THE BONE MARROW FROM A HLA-COMPATIBLE UNRELATED DONOR AFTER IMMUNOABLATIVE CONDITIONING IN CHILDREN WITH ACQUIRED APLASTIC ANEMIA UNRESPONSIVE TO COMBINED IMMUNOSUPPRESSIVE THERAPY: PRELIMINARY RESULTS

被引:0
作者
Novichkova, G. A. [1 ]
Maschan, M. A. [1 ]
Shipitsyna, I. P. [2 ]
Skvortsova, Yu. V. [2 ]
Persiantseva, M. I. [1 ]
Lebedeva, L. L.
Bobrynina, V. O. [1 ]
Baidildina, D. D. [2 ]
Goronkova, O. V. [2 ]
Solopova, G. G. [2 ]
Khachatryan, L. A. [1 ]
Petrova, U. N. [1 ]
Suntsova, E. V. [2 ]
Kalinina, I. I. [1 ]
Sinitsyna, V. V. [1 ]
Skorobogatova, E. V. [2 ]
Balashov, D. N. [1 ,2 ]
Dyshlevaya, Z. M. [2 ]
Shelikhova, L. N. [2 ]
Kurnikova, E. E. [2 ]
Trakhtman, P. E. [2 ]
Maschan, A. A. [1 ]
机构
[1] Minist Hlth Russian Federat, Fed Res & Clin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia
[2] Russian Childrens Hosp, Moscow, Russia
关键词
children; acquired aplastic anemia; transplantation; unrelated donors; tacrolimus; thoracoabdominal irradiation; ANTI-THYMOCYTE GLOBULIN; COLONY-STIMULATING FACTOR; ANTITHYMOCYTE GLOBULIN; ALTERNATIVE DONOR; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE; GRAFT; RISK;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST. Subjects and methods. The study enrolled 14 children aged 2-16 years (median 9 years). A control group comprised 26 patients in whom IST was continued. The median interval between the diagnosis of AA and transplantation was 26 months (9-156 months). The conditioning regimen consisted of thoracoabdominal irradiation in a dose of 2 Gy, fludarabin (Flu) 100-150 mg/m(2), cyclophosphamide (Cy) 100-200 mg/kg, antithymocyte globulin (ATG) in 11 patients and Flu, Cy, and ATG in 3. A graft-versus-host reaction was prevented with mycophenolate mefetil in all the patients, tacrolimus in 11, and cyclosporin A in 3. Donors were compatible for high-resolution typing of 10/10 and 9/10 alleles in 8 and 6 patients, respectively; the source of a transplant was bone marrow in 13 patients and granulocyte colony-stimulating factor-mobilized peripheral blood precursors in one case. Results. Thirteen patients achieved primary engraftment after single transplantation; one patient did after repeat transplantation. Grades I to II graft-versus-host reaction (GVHR) developed in 9 patients; post engraftment life-threatening infections in 3, extensive chronic GVHR in 2, circumscribed GVHR in 7. All fourteen hemopoietic cell transplant recipients followed for a median 17.5 months (range 1-71 months) were survivors. Conclusion. The likelihood of good survival after unrelated transplantations in AA is much higher than that after continued IST: 100% versus 15 +/- 11%.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 24 条
[1]   Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia:: a report from the EBMT-SAA Working Party [J].
Bacigalupo, A ;
Locatelli, F ;
Lanino, E ;
Marsh, J ;
Socié, G ;
Maury, S ;
Prete, A ;
Locasciulli, A ;
Cesaro, S ;
Passweg, J .
BONE MARROW TRANSPLANTATION, 2005, 36 (11) :947-950
[2]   Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia [J].
Buyck, H. C. E. ;
Ball, S. ;
Junagade, P. ;
Marsh, J. ;
Chakrabarti, S. .
BONE MARROW TRANSPLANTATION, 2009, 43 (10) :813-816
[3]  
CAMITTA B, 1989, BLOOD, V74, P1852
[4]  
CAMITTA BM, 1979, BLOOD, V53, P504
[5]   Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation [J].
Deeg, HJ ;
Amylon, MD ;
Harris, RE ;
Collins, R ;
Beatty, PG ;
Feig, S ;
Ramsay, N ;
Territo, M ;
Khan, SP ;
Pamphilon, D ;
Leis, JF ;
Burdach, S ;
Anasetti, C ;
Hackman, R ;
Storer, B ;
Mueller, B .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) :208-215
[6]   Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy [J].
Di Bona, E ;
Rodeghiero, E ;
Bruno, B ;
Gabbas, A ;
Foa, P ;
Locasciulli, A ;
Rosanelli, C ;
Camba, L ;
Saracco, P ;
Lippi, A ;
Iori, AP ;
Porta, F ;
De Rossi, V ;
Comotti, B ;
Iacopino, P ;
Dufour, C ;
Bacigalupo, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (02) :330-334
[7]   Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia [J].
Fuehrer, M. .
BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 2) :S97-S100
[8]   Immunosuppressive therapy for aplastic anemia in children:: a more severe disease predicts better survival [J].
Führer, M ;
Rampf, U ;
Baumann, I ;
Faldum, A ;
Niemeyer, C ;
Janka-Schaub, G ;
Friedrich, W ;
Ebell, W ;
Borkhardt, A ;
Bender-Goetze, C .
BLOOD, 2005, 106 (06) :2102-2104
[9]   Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA94 experience [J].
Fuhrer, M ;
Burdach, S ;
Ebell, W ;
Gadner, H ;
Haas, R ;
Harbott, J ;
Janka-Schaub, G ;
Klingebiel, T ;
Kremens, B ;
Niemeyer, C ;
Rampf, U ;
Reiter, A ;
Ritter, J ;
Schulz, A ;
Walther, U ;
Zeidler, C ;
Bender-Gotze, C .
KLINISCHE PADIATRIE, 1998, 210 (04) :173-179
[10]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304